<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7230963\results\search\disease\results.xml">
  <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Severe" exact="influenza" post="is associated with high morbidity and mortality. The aim"/>
  <result pre="investigate the factors affecting the clinical outcomes of critically ill" exact="influenza" post="patients. In this retrospective study, we enrolled critically ill"/>
  <result pre="this retrospective study, we enrolled critically ill adult patients with" exact="influenza" post="at the Kaohsiung Chang Gung Memorial Hospital in Taiwan."/>
  <result pre="associations with mortality. Between 2015 and 2018, 102 critically ill" exact="influenza" post="patients (median age, 62 years) were assessed; among them,"/>
  <result pre="illness. Of the 102 patients, the major influenza-associated complications were" exact="respiratory failure" post="(97%), pneumonia (94.1%), acute kidney injury (65.7%), adult respiratory"/>
  <result pre="102 patients, the major influenza-associated complications were respiratory failure (97%)," exact="pneumonia" post="(94.1%), acute kidney injury (65.7%), adult respiratory distress syndrome"/>
  <result pre="gastrointestinal bleeding were independent predictors of mortality in critically ill" exact="influenza" post="patients. The optimal lactate level cutoff for predicting mortality"/>
  <result pre="mortality that could aid in the care of critically ill" exact="influenza" post="patients. Identification of these prognostic markers could be improved"/>
  <result pre="examinations that might be useful in determining patient outcomes. severe" exact="influenza" post="pneumonia acute respiratory distress syndrome lactate mortality 1. Introduction"/>
  <result pre="that might be useful in determining patient outcomes. severe influenza" exact="pneumonia" post="acute respiratory distress syndrome lactate mortality 1. Introduction Influenza"/>
  <result pre="might be useful in determining patient outcomes. severe influenza pneumonia" exact="acute respiratory distress syndrome" post="lactate mortality 1. Introduction Influenza is an acute viral"/>
  <result pre="an acute viral respiratory infection caused by different types of" exact="influenza" post="viruses: influenza A, B, and C [1]. Influenza A"/>
  <result pre="viral respiratory infection caused by different types of influenza viruses:" exact="influenza" post="A, B, and C [1]. Influenza A subtypes H1N1,"/>
  <result pre="B, and C [1]. Influenza A subtypes H1N1, H3N2, and" exact="influenza" post="B are the most common causes of human influenza"/>
  <result pre="and influenza B are the most common causes of human" exact="influenza" post="[1]. The illness is usually mild and characterized by"/>
  <result pre="patients [2,3]. Annually, the World Health Organization estimated that global" exact="influenza" post="epidemics result in 3 to 5 million cases of"/>
  <result pre="and 290,000 to 650,000 deaths [4,5]. In 2009, a swine-origin" exact="influenza" post="A (pandemic 2009 A/H1N1; pdm09 A/H1) emerged and rapidly"/>
  <result pre="the United States due to pdm09 A/H1 [7]. Severe complicated" exact="influenza" post="has a significantly high mortality and morbidity [8,9]. Secondary"/>
  <result pre="influenza has a significantly high mortality and morbidity [8,9]. Secondary" exact="bacterial pneumonia" post="and acute respiratory distress syndrome (ARDS) are some of"/>
  <result pre="has a significantly high mortality and morbidity [8,9]. Secondary bacterial" exact="pneumonia" post="and acute respiratory distress syndrome (ARDS) are some of"/>
  <result pre="significantly high mortality and morbidity [8,9]. Secondary bacterial pneumonia and" exact="acute respiratory distress syndrome" post="(ARDS) are some of the common pulmonary complications of"/>
  <result pre="rhabdomyolysis have also been reported to be associated with either" exact="influenza" post="A or B [11,12,13]. While early antiviral therapy may"/>
  <result pre="B [11,12,13]. While early antiviral therapy may reduce complications of" exact="influenza" post="[14,15,16], the majority of patients tend to delay seeking"/>
  <result pre="can help clinicians deliver the necessary management to critically ill" exact="influenza" post="patients in a timely manner. In the present study,"/>
  <result pre="clinical course and laboratory data of critically ill patients with" exact="influenza" post="and then explored the risk factors independently associated with"/>
  <result pre="all critically ill adult patients (aged ≥18 years) with laboratory-confirmed" exact="influenza" post="infection admitted between 2015 and 2018, at the Kaohsiung"/>
  <result pre="surgical intensive care units (ICUs) in Taiwan. Included critically ill" exact="influenza" post="patients were those admitted to an ICU, or those"/>
  <result pre="outpatients; or if they had mild flu-like symptoms. Confirmation of" exact="influenza" post="virus infection required a positive finding in the respiratory"/>
  <result pre="swab) by one or more of the following methods: rapid" exact="influenza" post="diagnostic test (Formosa One Sure Flu A/B Rapid Test"/>
  <result pre="TAIGEN Bioscience Corporation, Taiwan). The choice of diagnostic test (rapid" exact="influenza" post="diagnostic test, virus isolation or RT-PCR) for confirming influenza"/>
  <result pre="(rapid influenza diagnostic test, virus isolation or RT-PCR) for confirming" exact="influenza" post="was based on the individual physicians’ judgment. 2.2. Data"/>
  <result pre="during the entire clinical course, in-hospital complications, and fatality. Acute" exact="respiratory failure" post="was defined as arterial partial pressure of oxygen (PaO2)"/>
  <result pre="ratio &amp;lt;300 mmHg) in the absence of evidence for cardiogenic" exact="pulmonary edema" post="[17]. Fulminant hepatitis meant alanine aminotransferase levels (ALT) greater"/>
  <result pre="the absence of evidence for cardiogenic pulmonary edema [17]. Fulminant" exact="hepatitis" post="meant alanine aminotransferase levels (ALT) greater than 16.6 µkat/L."/>
  <result pre="of encephalitis, and (6) abnormal findings on electroencephalography consistent with" exact="encephalitis" post="[18]. A galactomannan cutoff optical density index of &amp;gt;0.5"/>
  <result pre="Analysis To analyze the predictors of mortality among critically ill" exact="influenza" post="patients, we initially compared demographic, clinical characteristics, and laboratory"/>
  <result pre="model to identify independent predictors of mortality in critically ill" exact="influenza" post="patients. We used receiver operating characteristic curves (ROC) to"/>
  <result pre="women, with a median age of 62 years with laboratory-confirmed" exact="influenza" post="virus infection were assessed. The median time from illness"/>
  <result pre="48 h after the onset of symptoms. Among 102 patients," exact="influenza" post="A virus was detected in 77 (75.5%) patients (33.3%"/>
  <result pre="for pdm09 A/H1, 7.8% for H3N2 and 28.4% for untypable" exact="influenza" post="A), influenza B virus in 24 (23.5%), and concurrent"/>
  <result pre="A/H1, 7.8% for H3N2 and 28.4% for untypable influenza A)," exact="influenza" post="B virus in 24 (23.5%), and concurrent influenza A"/>
  <result pre="influenza A), influenza B virus in 24 (23.5%), and concurrent" exact="influenza" post="A (untypable) and influenza B in 1 (0.9%). The"/>
  <result pre="virus in 24 (23.5%), and concurrent influenza A (untypable) and" exact="influenza" post="B in 1 (0.9%). The clinical characteristics of the"/>
  <result pre="during the entire clinical course. The five common complications were" exact="respiratory failure" post="(97%), pneumonia (94.1%), acute kidney injury (65.7%), ARDS (51%),"/>
  <result pre="clinical course. The five common complications were respiratory failure (97%)," exact="pneumonia" post="(94.1%), acute kidney injury (65.7%), ARDS (51%), and gastrointestinal"/>
  <result pre="(11.7%) noninvasively. The median time from illness onset to acute" exact="respiratory failure" post="was four days (range, 1–27). Inotropes or vasopressors were"/>
  <result pre="were treated with ECMO, of whom 15 (88.2%) patients had" exact="influenza" post="A virus and 2 (11.7%) had influenza B virus"/>
  <result pre="(88.2%) patients had influenza A virus and 2 (11.7%) had" exact="influenza" post="B virus infection. The median duration of ECMO support"/>
  <result pre="10), gastrointestinal bleeding (n = 8), rhabdomyolysis (n = 4)," exact="pneumothorax" post="(n = 2), intracranial hemorrhage (n = 1), and"/>
  <result pre="(n = 2), intracranial hemorrhage (n = 1), and fulminant" exact="hepatitis" post="(n = 1) were the most common conditions contributing"/>
  <result pre="days after symptom onset. Of 41 deceased patients, 80.5% had" exact="influenza" post="A virus and 19.5% had influenza B virus infection."/>
  <result pre="deceased patients, 80.5% had influenza A virus and 19.5% had" exact="influenza" post="B virus infection. Of the 38 deceased patients who"/>
  <result pre="of the illness (Table 4). Among the 41 deceased patients," exact="pneumonia" post="developed in 39 (95.1%) patients, acute kidney injury in"/>
  <result pre="= 0.025) were independent predictors of mortality in critically ill" exact="influenza" post="patients (Table 5). 3.6. Event-Based Algorithm The median highest"/>
  <result pre="4. Discussion In a study involving 444 adult patients with" exact="influenza" post="in hospitals in the United States, the mortality rate"/>
  <result pre="in their study of 2059 patients admitted to ICUs for" exact="influenza" post="infection [22]. In our study, a mortality rate as"/>
  <result pre="influenza. However, which variables can predict poor patient outcomes after" exact="influenza" post="virus infection remain to be elucidated. In the present"/>
  <result pre="help clinicians deliver timely and sufficient treatment to critically ill" exact="influenza" post="patients. Our results underscore that high blood lactate levels"/>
  <result pre="bleeding were independent risk factors of mortality in critically ill" exact="influenza" post="patients. High blood lactate levels indicate tissue hypoxia due"/>
  <result pre="significantly and independently associated with fatal outcomes in critically ill" exact="influenza" post="patients. In addition, nonsurvivors had a significantly higher prevalence"/>
  <result pre="marker assisting clinicians in predicting the outcomes in critically ill" exact="influenza" post="patients. Our series here showed gastrointestinal bleeding occurred in"/>
  <result pre="to possible gastrointestinal bleeding when caring for a critically ill" exact="influenza" post="patient because this complication potentially leads to death if"/>
  <result pre="early and treated accordingly. ARDS is a lethal complication of" exact="influenza" post="infection [25]. Ortiz et al. estimated that the incidence"/>
  <result pre="Ortiz et al. estimated that the incidence of influenza-associated acute" exact="respiratory failure" post="was 2.7 events per 100,000 person–years [26]. In a"/>
  <result pre="of 58 patients with ARDS, 28 (48.2%) were due to" exact="influenza" post="virus infection, and 32.1% of the patients with influenza-associated"/>
  <result pre="an independent risk factor for hospital mortality in critically ill" exact="influenza" post="patients, and the mortality rate can be as high"/>
  <result pre="are consistent with previous findings wherein 97% of critically ill" exact="influenza" post="patients developed acute respiratory failure with a median time"/>
  <result pre="findings wherein 97% of critically ill influenza patients developed acute" exact="respiratory failure" post="with a median time of four days between illness"/>
  <result pre="a median time of four days between illness onset and" exact="respiratory failure," post="and 51% of them subsequently developed ARDS during their"/>
  <result pre="the patients with influenza-associated ARDS required ECMO for profound hypoxemic" exact="respiratory failure." post="Our study highlights that severe oxygenation failure occurred rapidly"/>
  <result pre="ICU resources to meet this treatment requirement, particularly during the" exact="influenza" post="epidemic. In the present study, we established a simple"/>
  <result pre="lactate level and ARDS for timely detection of critically ill" exact="influenza" post="patients who are at greater risk of mortality. Notably,"/>
  <result pre="who are at greater risk of mortality. Notably, critically ill" exact="influenza" post="patients without ARDS but with a blood lactate concentration"/>
  <result pre="that developed ARDS. In contrast, only 7.7% of critically ill" exact="influenza" post="patients without ARDS and with normal blood lactate levels"/>
  <result pre="levels died. Considering the high mortality rate among critically ill" exact="influenza" post="patients, this event-based algorithm could aid in the timely"/>
  <result pre="the importance of early treatment with antivirals in critically ill" exact="influenza" post="patients cannot be overemphasized. In our study, bacteremia was"/>
  <result pre="was caused by Staphylococcus aureus. A report of the 2009–2010" exact="influenza" post="pandemic among critically ill children revealed that nearly 5%"/>
  <result pre="poor outcomes were found among patients who were coinfected with" exact="influenza" post="viruses and Staphylococcus aureus [34]. Although we were unable"/>
  <result pre="or not initiating timely additional antimicrobial treatment in critically ill" exact="influenza" post="patients led to better clinical outcomes, our findings and"/>
  <result pre="most important cause of bacterial coinfection in pediatric and adult" exact="influenza" post="patients. Invasive pulmonary Aspergillus as a coinfection in patients"/>
  <result pre="Invasive pulmonary Aspergillus as a coinfection in patients with severe" exact="influenza" post="has been described [35,36,37]. In a cohort study involving"/>
  <result pre="cohort study involving seven ICUs over a period of seven" exact="influenza" post="seasons showed that influenza and the use of corticosteroids"/>
  <result pre="ICUs over a period of seven influenza seasons showed that" exact="influenza" post="and the use of corticosteroids were independent risk factors"/>
  <result pre="the use of corticosteroids were independent risk factors for invasive" exact="aspergillosis" post="[35]. In the present study, invasive pulmonary aspergillosis was"/>
  <result pre="for invasive aspergillosis [35]. In the present study, invasive pulmonary" exact="aspergillosis" post="was confirmed in two deceased influenza patients with high"/>
  <result pre="present study, invasive pulmonary aspergillosis was confirmed in two deceased" exact="influenza" post="patients with high galactomannan index in bronchoalveolar lavage fluid."/>
  <result pre="that clinicians should be aware of the risk of invasive" exact="aspergillosis" post="in critically ill influenza patients, particularly immunocompromised patients or"/>
  <result pre="aware of the risk of invasive aspergillosis in critically ill" exact="influenza" post="patients, particularly immunocompromised patients or those receiving corticosteroids. Further"/>
  <result pre="the incidence, risk factors, and clinical features of invasive pulmonary" exact="aspergillosis" post="in influenza patients. In 2003, an avian influenza virus"/>
  <result pre="risk factors, and clinical features of invasive pulmonary aspergillosis in" exact="influenza" post="patients. In 2003, an avian influenza virus of H5N1"/>
  <result pre="of invasive pulmonary aspergillosis in influenza patients. In 2003, an" exact="avian influenza" post="virus of H5N1 subtype was isolated from a smuggled"/>
  <result pre="invasive pulmonary aspergillosis in influenza patients. In 2003, an avian" exact="influenza" post="virus of H5N1 subtype was isolated from a smuggled"/>
  <result pre="pneumococcus and influenza, and some missing laboratory data such as" exact="pneumonia" post="severity index and coagulation profile, were not collected. Second,"/>
  <result pre="the key factors associated with poor outcomes for critically ill" exact="influenza" post="patients and established a decision-making algorithm that can take"/>
  <result pre="the prediction of the poor outcomes in hospitalized critically ill" exact="influenza" post="patients, as timely intensive supportive care might be lifesaving."/>
  <result pre="services and ICUs can be overwhelmed during the peak of" exact="influenza" post="epidemics, particularly in point-of-care resource-limited areas. Our findings could"/>
  <result pre="primary care at the initial clinical evaluation of critically ill" exact="influenza" post="patients. Acknowledgments We thank the staff members in the"/>
  <result pre="(H1N1) Virus Investigation Team. Emergence of a novel swine origin" exact="influenza" post="A (H1N1) virus in humansN. Engl. J. Med.20093602605261510.1056/nejmoa090381019423869 7.ShresthaS.S.SwerdlowD.L.BorseR.H.PrabhuV.S.FinelliL.AtkinsC.Y.Owusu-EduseiK.BellB.MeadP.S.BiggerstallM.et"/>
  <result pre="Engl. J. Med.20093602605261510.1056/nejmoa090381019423869 7.ShresthaS.S.SwerdlowD.L.BorseR.H.PrabhuV.S.FinelliL.AtkinsC.Y.Owusu-EduseiK.BellB.MeadP.S.BiggerstallM.et al.Estimating the burden of 2009 pandemic" exact="influenza" post="A (H1N1) in the United States (April 2009–April 2010)Clin."/>
  <result pre="Infect. Dis.201152S75S8210.1093/cid/ciq01221342903 8.ZhouF.LiH.GuL.LiuM.XueC.X.CaoB.WangC.Risk factors for nosocomial infection among hospitalised severe" exact="influenza" post="A(H1N1)pdm09 patientsRespir. Med.2018134869110.1016/j.rmed.2017.11.01729413513 9.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnersM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.Myocardial injury and bacterial pneumonia contribute"/>
  <result pre="among hospitalised severe influenza A(H1N1)pdm09 patientsRespir. Med.2018134869110.1016/j.rmed.2017.11.01729413513 9.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnersM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.Myocardial injury and" exact="bacterial pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
  <result pre="hospitalised severe influenza A(H1N1)pdm09 patientsRespir. Med.2018134869110.1016/j.rmed.2017.11.01729413513 9.PaddockC.D.LiuL.DenisonA.M.BartlettJ.H.HolmanR.C.Deleon-CarnersM.EmeryS.L.DrewC.P.ShiehW.J.UyekiT.M.Myocardial injury and bacterial" exact="pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
  <result pre="injury and bacterial pneumonia contribute to the pathogenesis of fatal" exact="influenza" post="B virus infectionJ. Infect. Dis.201220589590510.1093/infdis/jir86122291193 10.DaoudA.LaktinehA.MacranderC.MushtaqA.SoubaniA.O.Pulmonary complications of influenza"/>
  <result pre="fatal influenza B virus infectionJ. Infect. Dis.201220589590510.1093/infdis/jir86122291193 10.DaoudA.LaktinehA.MacranderC.MushtaqA.SoubaniA.O.Pulmonary complications of" exact="influenza" post="infection: A targeted narrative reviewPostgrad. Med.201913129930810.1080/00325481.2019.159240030845866 11.KumarA.ZarychanskiR.PintoR.CookD.J.MarshallJ.LacroixJ.StelfoxT.BagshawS.ChoongK.LamontagneF.Canadian Critical Care"/>
  <result pre="Care Trials Group H1N1 Collaborative. Critically ill patients with 2009" exact="influenza" post="A (H1N1) infection in CanadaJAMA20093021872187910.1001/jama.2009.149619822627 12.RelloJ.RodríguezA.IbañezP.SociasL.CebrianJ.MarquesA.GuerreroJ.Ruiz-SantanaS.MarquezE.Nogel-SaezF.D.H1N1 SEMICYUC Working Group."/>
  <result pre="12.RelloJ.RodríguezA.IbañezP.SociasL.CebrianJ.MarquesA.GuerreroJ.Ruiz-SantanaS.MarquezE.Nogel-SaezF.D.H1N1 SEMICYUC Working Group. Intensive care adult patients with severe" exact="respiratory failure" post="caused by Influenza A (H1N1)v in SpainCrit. Care200913R14810.1186/cc804419747383 13.Domínguez-CheritG.LapinskyS.E.MaciasA.E.PintoR.Espinosa-PerezL.de"/>
  <result pre="in SpainCrit. Care200913R14810.1186/cc804419747383 13.Domínguez-CheritG.LapinskyS.E.MaciasA.E.PintoR.Espinosa-PerezL.de la TorreA.Poblano-MoralesM.Baltazar-TorresJ.A.BautistaE.MartinezA.Critically Ill patients with 2009" exact="influenza" post="A(H1N1) in MexicoJAMA20093021880188710.1001/jama.2009.153619822626 14.DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir treatment for influenza in adults:"/>
  <result pre="patients with 2009 influenza A(H1N1) in MexicoJAMA20093021880188710.1001/jama.2009.153619822626 14.DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir treatment for" exact="influenza" post="in adults: A meta analysis of randomised controlled trialsLancet20153851729173710.1016/S0140-6736(14)62449-125640810"/>
  <result pre="randomised controlled trialsLancet20153851729173710.1016/S0140-6736(14)62449-125640810 15.DollM.K.WintersN.BoikosC.Kraicer-MelamedH.GoreG.QuachC.Safety and effectiveness of neuraminidase inhibitors for" exact="influenza" post="treatment, prophylaxis, and outbreak control: A systematic review of"/>
  <result pre="treatment started within 5 days of symptom onset to reduce" exact="influenza" post="illness duration and virus shedding in an urban setting"/>
  <result pre="J. Neurol.201017e5710.1111/j.1468-1331.2010.02970.x 19.HeerK.D.GerritsenM.G.VisserC.E.LeeflangM.M.Galactomannan detection in broncho-alveolar lavage fluid for invasive" exact="aspergillosis" post="in immunocompromised patientsCochrane Database Syst. Rev.201910.1002/14651858.cd012399.pub2 20.MaertensJ.TheunissenK.VerbekenE.LagrouK.VerhaegenJ.BoogaertsM.EldereJ.V.Prospective clinical evaluation"/>
  <result pre="evaluation of lower cut-offs for galactomannan detection in adult neutropenic" exact="cancer" post="patients and haematological stem cell transplant recipientsBr. J. Haematol.200412685286010.1111/j.1365-2141.2004.05140.x15352990"/>
  <result pre="de MolinaF.J.Martín LoechesI.BarbadilloS.RodríguezA.H1N1 GETGAG/SEMICYUC Study Group. Delay in diagnosis of" exact="influenza" post="A (H1N1)pdm09 virus infection in critically ill patients and"/>
  <result pre="Acute Respiratory Distress SyndromeJAMA20093021888189510.1001/jama.2009.153519822628 29.LiG.YilmazM.KojicicM.Fernández-PérezE.WahabR.HuskinsW.C.AfessaB.TruwitJ.D.GajicO.Outcome of critically ill patients with" exact="influenza" post="virus infectionJ. Clin. Virol.20094627527810.1016/j.jcv.2009.07.01519699141 30.JainS.KamimotoL.BramleyA.M.SchmitzA.M.BenoitS.R.LouieJ.SugermanD.E.DruckenmillerJ.K.RitgerK.A.ChughR.Hospitalized Patients with 2009 H1N1"/>
  <result pre="late oseltamivir treatment in severely ill patients with 2009 pandemic" exact="influenza" post="A (H1N1): Speed is lifeJ. Antimicrob. Chemother.20116695996310.1093/jac/dkr09021406435 33.RandolphA.G.VaughnF.SullivanR.RubinsonL.ThompsonB.T.YoonG.SmootE.RiceT.W.LoftisL.L.HelfaerM.et al.Critically"/>
  <result pre="lifeJ. Antimicrob. Chemother.20116695996310.1093/jac/dkr09021406435 33.RandolphA.G.VaughnF.SullivanR.RubinsonL.ThompsonB.T.YoonG.SmootE.RiceT.W.LoftisL.L.HelfaerM.et al.Critically ill children during the 2009–2010" exact="influenza" post="pandemic in the United StatesPediatrics2011128e1450e145810.1542/peds.2011-077422065262 34.McDanelJ.S.PerencevichE.N.StormJ.DiekemaD.J.HerwaldtL.JohnsonJ.K.WinokurP.L.SchweizerM.L.Increased Mortality Rates Associated"/>
  <result pre="and Iowa, USAEmerg. Infect. Dis.2016221253125610.3201/eid2207.15131927315549 35.SchauwvliegheA.RijndersB.PhilipsN.VerwijsR.VanderbekeL.Van TienenC.LagrouK.VerweijP.E.Van de VeerdonkF.L.GommersD.et al.Invasive" exact="aspergillosis" post="in patients admitted to the intensive care unit with"/>
  <result pre="A retrospective cohort studyLancet Respir. Med.2018678279210.1016/S2213-2600(18)30274-130076119 36.WautersJ.BaarI.MeerssemanP.MeerssemanW.DamsK.De PaepR.LagrouK.WilmerA.JorensP.HermansG.et al.Invasive pulmonary" exact="aspergillosis" post="is a frequent complication of critically ill H1N1 patients:"/>
  <result pre="PatientsAm. J. Respir. Crit. Care Med.201719652452710.1164/rccm.201612-2540LE28387526 38.LeeM.S.DengM.C.LinY.J.ChangC.Y.ShiehH.K.ShiauJ.Z.HuangC.C.Characterization of an H5N1" exact="avian influenza" post="virus from TaiwanVet. Microbiol.200712419320110.1016/j.vetmic.2007.04.02117512143 39.GongY.N.KuoR.L.ChenG.W.ShihS.R.Centennial review of influenza in"/>
  <result pre="J. Respir. Crit. Care Med.201719652452710.1164/rccm.201612-2540LE28387526 38.LeeM.S.DengM.C.LinY.J.ChangC.Y.ShiehH.K.ShiauJ.Z.HuangC.C.Characterization of an H5N1 avian" exact="influenza" post="virus from TaiwanVet. Microbiol.200712419320110.1016/j.vetmic.2007.04.02117512143 39.GongY.N.KuoR.L.ChenG.W.ShihS.R.Centennial review of influenza in"/>
  <result pre="H5N1 avian influenza virus from TaiwanVet. Microbiol.200712419320110.1016/j.vetmic.2007.04.02117512143 39.GongY.N.KuoR.L.ChenG.W.ShihS.R.Centennial review of" exact="influenza" post="in TaiwanBiomed. J.20184123424110.1016/j.bj.2018.08.00230348266 Figure 1 Receiver operating characteristic curve"/>
  <result pre="(17.8–37.8) (n = 31) 0.583 Underlying condition, N (%) Bronchial" exact="asthma" post="7 (6.9) 4 (6.6) 3 (7.3) &amp;gt;0.99 Hypertension 56"/>
  <result pre="Hypertension 56 (54.9) 38 (62.3) 18 (43.9) 0.073 Type 2" exact="diabetes mellitus" post="45 (44.1) 28 (45.9) 17 (41.5) 0.689 Chronic kidney"/>
  <result pre="pulmonary disease 8 (7.8) 7 (11.5) 1 (2.4) 0.139 Liver" exact="cirrhosis" post="6 (5.9) 3 (4.9) 3 (7.3) 0.682 qSOFA, median"/>
  <result pre="&amp;lt;0.001 Diagnostic methods for influenza, N/total N (%) Positive of" exact="influenza" post="rapid test 51/93 (54.8) 34/56 (60.7) 17/37 (45.9) -"/>
  <result pre="(54.8) 34/56 (60.7) 17/37 (45.9) - Positive of RT-PCR for" exact="influenza" post="94/98 (95.9) 59/61 (96.7) 35/37 (94.6) - Positive of"/>
  <result pre="94/98 (95.9) 59/61 (96.7) 35/37 (94.6) - Positive of throat" exact="influenza" post="viral culture 37/95 (38.9) 23/59 (39) 14/36 (38.9) -"/>
  <result pre="Influenza B 24 (23.5) 16 (26.2) 8 (19.5) 0.483 Concurrent" exact="influenza" post="A a and B 1 (0.9) 1 (1.6) 0"/>
  <result pre="chain reaction; qSOFA, quick Sequential Organ Failure Assessment. a Untypable" exact="influenza" post="A. jcm-09-01073-t002_Table 2Table 2 Symptom/signs of patients with severe"/>
  <result pre="Chest pain 8 (7.8) 5 (8.2) 3 (7.3) &amp;gt;0.99 Skin" exact="rash" post="1 (1) 1 (1.6) 0 &amp;gt;0.99 Altered consciousness 16"/>
  <result pre="Survivors (n = 61) Nonsurvivors (n = 41) p Acute" exact="respiratory failure" post="99 (97) 58 (95.1) 41 (100) &amp;gt;0.99 Time from"/>
  <result pre="58 (95.1) 41 (100) &amp;gt;0.99 Time from onset illness to" exact="respiratory failure," post="day, median (range) 4 (1–27) (n = 99) 3.5"/>
  <result pre="= 58) 4 (1–27) 0.451 Time from hospital presentation to" exact="respiratory failure," post="day, median (range) 1 (1–21) (n = 99) 1"/>
  <result pre="Gastrointestinal bleeding 36 (35.3) 15 (24.6) 21 (51.2) 0.011 Fulminant" exact="hepatitis" post="9 (8.8) 6 (9.8) 3 (7.3) 0.737 Rhabdomyolysis 12"/>
 </snippets>
</snippetsTree>
